Hinthorn D R, Baker L H, Romig D A, Hassanein K, Liu C
Antimicrob Agents Chemother. 1976 Mar;9(3):498-501. doi: 10.1128/AAC.9.3.498.
Hepatotoxicity has been noted by several investigators during parenteral use of clindamycin, and some have reported that drug half-life is prolonged in the presence of liver disease. We administered 300 mg of clindamycin intravenously at 12-h intervals for 2 days to patients with acute and chronic hepatitis, cirrhosis, and controls to determine whether clindamycin will exacerbate preexisting hepatic dysfunction or whether drug excretion will be delayed in patients with liver disease as compared with controls. Exacerbation of hepatotoxicity was not found in this study. There was a small, but significant, delay in drug elimination between cirrhotics and controls, even after the first dose of clindamycin (P < 0.05); however, half-lives in all categories were in the range usually considered normal. We conclude that clindamycin can be used in liver disease in some circumstances, if proper precautions are exercised.
几位研究人员在克林霉素非肠道给药期间注意到了肝毒性，并且一些人报告称在存在肝脏疾病的情况下药物半衰期会延长。我们对患有急慢性肝炎、肝硬化的患者以及对照组患者每12小时静脉注射300毫克克林霉素，持续2天，以确定克林霉素是否会加重已有的肝功能障碍，或者与对照组相比，肝脏疾病患者的药物排泄是否会延迟。在本研究中未发现肝毒性加剧的情况。即使在首次注射克林霉素后，肝硬化患者与对照组之间的药物消除也存在轻微但显著的延迟（P < 0.05）；然而，所有类别中的半衰期都在通常被认为正常的范围内。我们得出结论，如果采取适当的预防措施，克林霉素在某些情况下可用于肝脏疾病患者。
